Molecular signals elicited by GPCR agonists in hypertension, cardiovascular remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?

Current Hypertension Reviews

Volumn 8, Issue 3, 2012, Pages 159-180

  Wang, Xiang ^a   Bosonea, Ana Maria ^a   Odenbach, Jeffrey ^a   Fernandez Patron, Carlos ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular fibrosis; Cardiovascular hypertrophy; G protein coupled receptors; Hypertension; Metalloproteinases; Signaling pathways

Indexed keywords

ADAM PROTEIN; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCINEURIN; CALCIUM; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR AGONIST; GELATINASE A; GELATINASE B; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; MATRILYSIN; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C BETA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE C; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION AND TRANSLATION; HEART CONTRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TRANSACTIVATION; VASCULAR SMOOTH MUSCLE;

EID: 84870203025     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/157340212803530420     Document Type: Article

References (276)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-52.
2. The World Health report 2002. Midwifery 2003; 19(1): 72-3.
3. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
4. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118(1): 10-24.
5. Rizzoni D, Agabiti-Rosei E. Relationships of cardiac function and structure to blood pressure rhythms. Ann NY Acad Sci 1996; 783: 159-71.
6. Zhang Y, Griendling KK, Dikalova A, Owens GK, Taylor WR. Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2. Hypertension 2005; 46(4): 732-7.
7. Schiffrin EL. Vascular stiffening and arterial compliance. Implications for systolic blood pressure. Am J Hypertens 2004; 17(12 Pt 2): 39S-48S.
8. Sorescu D. Smad3 mediates angiotensin II-and TGF-beta1-induced vascular fibrosis: Smad3 thickens the plot. Circ Res 2006; 98(8): 988-9.
9. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38(3 Pt 2): 581-7.
10. Rockman HA, Wachhorst SP, Mao L, Ross J, Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994; 266(6 Pt 2): H2468-75.
11. Muller P, Kazakov A, Jagoda P, Semenov A, Bohm M, Laufs U. ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload. Cardiovasc Res 2009; 83(1): 106-14.
12. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin IIstimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989; 13(4): 305-14.
13. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62(4): 749-56.
14. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402(6764): 884-8.
15. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 2004; 94(1): 68-76.
16. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280(5363): 574-7.
17. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109(6): 787-96.
18. Lu Y, Yang S. Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases. Tohoku J Exp Med 2009; 219(1): 17-23.
19. Griffin SA, Brown WC, MacPherson F, et al. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 1991; 17(5): 626-35.
20. Liao Y, Asakura M, Takashima S, et al. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 2004; 110(6): 692-9.
21. Biaggioni I. Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension 2008; 51(2): 168-71.
22. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembranespanning receptors and heart function. Nature 2002; 415(6868): 206-12.
23. Cook B, Bar-Yaacov M, Cohen Ben-Ami H, et al. Phospholipase C and termination of G-protein-mediated signalling in vivo. Nat Cell Biol 2000; 2(5): 296-301.
24. Brock C, Schaefer M, Reusch HP, et al. Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. J Cell Biol 2003; 160(1): 89-99.
25. Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 1994; 369(6479): 418-20.
26. Inglese J, Koch WJ, Touhara K, Lefkowitz RJ. G beta gamma interactions with PH domains and Ras-MAPK signaling pathways. Trends Biochem Sci 1995; 20(4): 151-6.
27. Lorenz K, Schmitt JP, Schmitteckert EM, Lohse MJ. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009; 15(1): 75-83.
28. Sun Y, Yamauchi J, Kaziro Y, Itoh H. Activation of c-fos promoter by Gbetagamma-mediated signaling: involvement of Rho and c-Jun N-terminal kinase. J Biochem 1999; 125(3): 515-21.
29. Kamm KE, Stull JT. Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem 2001; 276(7): 4527-30.
30. Kordowska J, Huang R, Wang CL. Phosphorylation of caldesmon during smooth muscle contraction and cell migration or proliferation. J Biomed Sci 2006; 13(2): 159-72.
31. Gordon AM, Regnier M, Homsher E. Skeletal and cardiac muscle contractile activation: tropomyosin "rocks and rolls". News Physiol Sci 2001; 16: 49-55.
32. Kanaya N, Gable B, Murray PA, Damron DS. Propofol increases phosphorylation of troponin I and myosin light chain 2 via protein kinase C activation in cardiomyocytes. Anesthesiology 2003; 98(6): 1363-71.
33. Monasky MM, Biesiadecki BJ, Janssen PM. Increased phosphorylation of tropomyosin, troponin I, and myosin light chain-2 after stretch in rabbit ventricular myocardium under physiological conditions. J Mol Cell Cardiol 2010; 48(5): 1023-8.
34. Magid NM, Borer JS, Young MS, Wallerson DC, DeMonteiro C. Suppression of protein degradation in progressive cardiac hypertrophy of chronic aortic regurgitation. Circulation 1993; 87(4): 1249-57.
35. Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA 2000; 97(8): 4070-5.
36. Vega RB, Harrison BC, Meadows E, et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 2004; 24(19): 8374-85.
37. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. Expression of the beta (slow)-isoform of MHC in the adult mouse heart causes dominant-negative functional effects. Am J Physiol Heart Circ Physiol 2000; 278(2): H412-9.
38. Hewett TE, Grupp IL, Grupp G, Robbins J. Alpha-skeletal actin is associated with increased contractility in the mouse heart. Circ Res 1994; 74(4): 740-6.
39. Krenz M, Sanbe A, Bouyer-Dalloz F, et al. Analysis of myosin heavy chain functionality in the heart. J Biol Chem 2003; 278(19): 17466-74.
40. Proud CG. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004; 63(3): 403-13.
41. Dorn GW, 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115(3): 527-37.
42. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106(11): 1675-80.
43. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63(3): 423-32.
44. Fukuda N, Hu WY, Kubo A, et al. Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells. Am J Hypertens 2000; 13(2): 191-8.
45. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14(2): 163-76.
46. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997; 322 (Pt 3): 809-14.
47. Lonn P, Moren A, Raja E, Dahl M, Moustakas A. Regulating the stability of TGFbeta receptors and Smads. Cell Res 2009; 19(1): 21-35.
48. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-betaindependent mechanism. Circulation 2005; 111(19): 2509-17.
49. Wang W, Huang XR, Canlas E, et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006; 98(8): 1032-9.
50. Lee CH, Park D, Wu D, Rhee SG, Simon MI. Members of the Gq alpha subunit gene family activate phospholipase C beta isozymes. J Biol Chem 1992; 267(23): 16044-7.
51. Boyer JL, Waldo GL, Harden TK. Beta gamma-subunit activation of G-protein-regulated phospholipase C. J Biol Chem 1992; 267(35): 25451-6.
52. Camps M, Carozzi A, Schnabel P, Scheer A, Parker PJ, Gierschik P. Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits. Nature 1992; 360(6405): 684-6.
53. Kelso EJ, McDermott BJ, Silke B, Spiers JP. Endothelin(A) receptor subtype mediates endothelin-induced contractility in left ventricular cardiomyocytes isolated from rabbit myocardium. J Pharmacol Exp Ther 2000; 294(3): 1047-52.
54. Schelling JR, Nkemere N, Konieczkowski M, Martin KA, Dubyak GR. Angiotensin II activates the beta 1 isoform of phospholipase C in vascular smooth muscle cells. Am J Physiol 1997; 272(5 Pt 1): C1558-66.
55. Filtz TM, Grubb DR, McLeod-Dryden TJ, Luo J, Woodcock EA. Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase Cbeta1b. Faseb J 2009; 23(10): 3564-70.
56. Viard P, Exner T, Maier U, Mironneau J, Nurnberg B, Macrez N. Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. Faseb J 1999; 13(6): 685-94.
57. Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 1997; 49(1): 1-51.
58. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004; 322(4): 1178-91.
59. Naruse K, King GL. Protein kinase C and myocardial biology and function. Circ Res 2000; 86(11): 1104-6.
60. Rusanescu G, Gotoh T, Tian X, Feig LA. Regulation of Ras signaling specificity by protein kinase C. Mol Cell Biol 2001; 21(8): 2650-8.
61. Clerk A, Sugden PH. Signaling through the extracellular signalregulated kinase 1/2 cascade in cardiac myocytes. Biochem Cell Biol 2004; 82(6): 603-9.
62. Clerk A, Bogoyevitch MA, Anderson MB, Sugden PH. Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogenactivated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J Biol Chem 1994; 269(52): 32848-57.
63. Pacold ME, Suire S, Perisic O, et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000; 103(6): 931-43.
64. Marais R, Light Y, Mason C, Paterson H, Olson MF, Marshall CJ. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science 1998; 280(5360): 109-12.
65. Nakashima H, Frank GD, Shirai H, et al. Novel role of protein kinase C-delta Tyr 311 phosphorylation in vascular smooth muscle cell hypertrophy by angiotensin II. Hypertension 2008; 51(2): 232-8.
66. Vijayan K, Szotek EL, Martin JL, Samarel AM. Protein kinase Calpha-induced hypertrophy of neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2004; 287(6): H2777-89.
67. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res 2000; 86(12): 1218-23.
68. Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997; 94(17): 9320-5.
69. Walsh MP, Horowitz A, Clement-Chomienne O, Andrea JE, Allen BG, Morgan KG. Protein kinase C mediation of Ca(2+)-independent contractions of vascular smooth muscle. Biochem Cell Biol 1996; 74(4): 485-502.
70. Walsh MP, Susnjar M, Deng J, Sutherland C, Kiss E, Wilson DP. Phosphorylation of the protein phosphatase type 1 inhibitor protein CPI-17 by protein kinase C. Methods Mol Biol 2007; 365: 209-23.
71. Venema RC, Raynor RL, Noland TA, Jr., Kuo JF. Role of protein kinase C in the phosphorylation of cardiac myosin light chain 2. Biochem J 1993; 294 (Pt 2): 401-6.
72. Clement O, Puceat M, Walsh MP, Vassort G. Protein kinase C enhances myosin light-chain kinase effects on force development and ATPase activity in rat single skinned cardiac cells. Biochem J 1992; 285 (Pt 1): 311-7.
73. Xu X, Ha CH, Wong C, et al. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler Thromb Vasc Biol 2007; 27(11): 2355-62.
74. Monovich L, Vega RB, Meredith E, et al. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. FEBS Lett 2010; 584(3): 631-7.
75. Wang Y, Waldron RT, Dhaka A, et al. The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol 2002; 22(3): 916-26.
76. Fielitz J, Kim MS, Shelton JM, et al. Requirement of protein kinase D1 for pathological cardiac remodeling. Proc Natl Acad Sci USA 2008; 105(8): 3059-63.
77. Nagao S, Yamaguchi T, Kusaka M, et al. Renal activation of extracellular signal-regulated kinase in rats with autosomaldominant polycystic kidney disease. Kidney Int 2003; 63(2): 427-37.
78. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardialdirected overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000; 32(5): 817-30.
79. Antos CL, Frey N, Marx SO, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a. Circ Res 2001; 89(11): 997-1004.
80. Harrison JG, Sugden PH, Clerk A. Endothelin-1 promotes phosphorylation of CREB transcription factor in primary cultures of neonatal rat cardiac myocytes: implications for the regulation of c-jun expression. Biochim Biophys Acta 2004; 1644(1): 17-25.
81. Markou T, Hadzopoulou-Cladaras M, Lazou A. Phenylephrine induces activation of CREB in adult rat cardiac myocytes through MSK1 and PKA signaling pathways. J Mol Cell Cardiol 2004; 37(5): 1001-11.
82. Ichiki T. Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both? Arterioscler Thromb Vasc Biol 2006; 26(3): 449-55.
83. Wang Z, Dillon TJ, Pokala V, et al. Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. Mol Cell Biol 2006; 26(6): 2130-45.
84. Metrich M, Lucas A, Gastineau M, et al. Epac mediates betaadrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 2008; 102(8): 959-65.
85. Morel E, Marcantoni A, Gastineau M, et al. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ Res 2005; 97(12): 1296-304.
86. Bueno OF, De Windt LJ, Tymitz KM, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. Embo J 2000; 19(23): 6341-50.
87. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004; 110(6): 718-23.
88. Downward J, Graves JD, Warne PH, Rayter S, Cantrell DA. Stimulation of p21ras upon T-cell activation. Nature 1990; 346(6286): 719-23.
89. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 1996; 271(38): 23512-9.
90. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999; 11(2): 211-8.
91. Babu GJ, Lalli MJ, Sussman MA, Sadoshima J, Periasamy M. Phosphorylation of elk-1 by MEK/ERK pathway is necessary for cfos gene activation during cardiac myocyte hypertrophy. J Mol Cell Cardiol 2000; 32(8): 1447-57.
92. Wang L, Proud CG. Ras/Erk signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ Res 2002; 91(9): 821-9.
93. Siddiqui RA, Shaikh SR, Kovacs R, Stillwell W, Zaloga G. Inhibition of phenylephrine-induced cardiac hypertrophy by docosahexaenoic acid. J Cell Biochem 2004; 92(6): 1141-59.
94. Takeishi Y, Huang Q, Abe J, et al. Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. J Mol Cell Cardiol 2001; 33(9): 1637-48.
95. Whitman M, Downes CP, Keeler M, Keller T, Cantley L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988; 332(6165): 644-6.
96. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296(5573): 1655-7.
97. Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000; 275(12): 8271-4.
98. Condorelli G, Drusco A, Stassi G, et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002; 99(19): 12333-8.
99. Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng YT. Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility--a new transgenic model. Am J Physiol Heart Circ Physiol 2008; 295(4): H1690-4.
100. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo J 2000; 19(11): 2537-48.
101. Hixon ML, Muro-Cacho C, Wagner MW, et al. Akt1/PKB upregulation leads to vascular smooth muscle cell hypertrophy and polyploidization. J Clin Invest 2000; 106(8): 1011-20.
102. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005; 115(8): 2108-18.
103. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004; 109(24): 3050-5.
104. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17(15): 1829-34.
105. Inoki K, Ouyang H, Li Y, Guan KL. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 2005; 69(1): 79-100.
106. Hannan RD, Jenkins A, Jenkins AK, Brandenburger Y. Cardiac hypertrophy: a matter of translation. Clin Exp Pharmacol Physiol 2003; 30(8): 517-27.
107. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005; 121(2): 179-93.
108. Kwon OY, Kwon IC, Song HK, Jeon H. Real-time imaging of NFAT nucleocytoplasmic shuttling with a photoswitchable fluorescence protein in live cells. Biochim Biophys Acta 2008; 1780(12): 1403-7.
109. Ding Q, Xia W, Liu JC, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005; 19(2): 159-70.
110. Ni YG, Berenji K, Wang N, et al. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation 2006; 114(11): 1159-68.
111. Skurk C, Izumiya Y, Maatz H, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005; 280(21): 20814-23.
112. Le Blanc C, Mironneau C, Barbot C, et al. Regulation of vascular L-type Ca2+ channels by phosphatidylinositol 3,4,5-trisphosphate. Circ Res 2004; 95(3): 300-7.
113. Quignard JF, Mironneau J, Carricaburu V, et al. Phosphoinositide 3-kinase gamma mediates angiotensin II-induced stimulation of Ltype calcium channels in vascular myocytes. J Biol Chem 2001; 276(35): 32545-51.
114. Komalavilas P, Mehta S, Wingard CJ, et al. PI3-kinase/Akt modulates vascular smooth muscle tone via cAMP signaling pathways. J Appl Physiol 2001; 91(4): 1819-27.
115. Klee CB, Crouch TH, Krinks MH. Calcineurin: a calcium-and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci USA 1979; 76(12): 6270-3.
116. Perrino BA, Ng LY, Soderling TR. Calcium regulation of calcineurin phosphatase activity by its B subunit and calmodulin. Role of the autoinhibitory domain. J Biol Chem 1995; 270(12): 7012.
117. Suzuki E, Nishimatsu H, Satonaka H, et al. Angiotensin II induces myocyte enhancer factor 2-and calcineurin/nuclear factor of activated T cell-dependent transcriptional activation in vascular myocytes. Circ Res 2002; 90(9): 1004-11.
118. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93(2): 215-28.
119. Goldspink PH, McKinney RD, Kimball VA, Geenen DL, Buttrick PM. Angiotensin II induced cardiac hypertrophy in vivo is inhibited by cyclosporin A in adult rats. Mol Cell Biochem 2001; 226(1-2): 83-8.
120. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370(Pt 3): 737-49.
121. Ha CH, Kim JY, Zhao J, et al. PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2010; 107(35): 15467-72.
122. Li H, Li W, Gupta AK, Mohler PJ, Anderson ME, Grumbach IM. Calmodulin kinase II is required for angiotensin II-mediated vascular smooth muscle hypertrophy. Am J Physiol Heart Circ Physiol 2010; 298(2): H688-98.
123. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004; 24(19): 8467-76.
124. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002; 110(4): 479-88.
125. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115(3): 500-8.
126. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15(2): 247-54.
127. Frank GD, Mifune M, Inagami T, et al. Distinct mechanisms of receptor and nonreceptor tyrosine kinase activation by reactive oxygen species in vascular smooth muscle cells: role of metalloprotease and protein kinase C-delta. Mol Cell Biol 2003; 23(5): 1581-9.
128. Yoshizumi M, Tsuchiya K, Suzaki Y, et al. Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway. Biochem Biophys Res Commun 2002; 293(5): 1458-65.
129. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009; 302(2): 148-58.
130. Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98(8): 794-9.
131. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001; 88(5): 529-35.
132. Ide T, Tsutsui H, Kinugawa S, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 2000; 86(2): 152-7.
133. Kimura S, Zhang GX, Nishiyama A, et al. Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide. Hypertension 2005; 45(3): 438-44.
134. Li JM, Wheatcroft S, Fan LM, Kearney MT, Shah AM. Opposing roles of p47phox in basal versus angiotensin II-stimulated alterations in vascular O2-production, vascular tone, and mitogenactivated protein kinase activation. Circulation 2004; 109(10): 1307-13.
135. Hirono Y, Yoshimoto T, Suzuki N, et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 2007; 148(4): 1688-96.
136. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidasedependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006; 71(2): 208-15.
137. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49(11): 1939-45.
138. Castilho RF, Kowaltowski AJ, Meinicke AR, Bechara EJ, Vercesi AE. Permeabilization of the inner mitochondrial membrane by Ca2+ ions is stimulated by t-butyl hydroperoxide and mediated by reactive oxygen species generated by mitochondria. Free Radic Biol Med 1995; 18(3): 479-86.
139. Gadelha FR, Thomson L, Fagian MM, Costa AD, Radi R, Vercesi AE. Ca2+-independent permeabilization of the inner mitochondrial membrane by peroxynitrite is mediated by membrane protein thiol cross-linking and lipid peroxidation. Arch Biochem Biophys 1997; 345(2): 243-50.
140. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991; 266(7): 4244-50.
141. Djordjevic T, Pogrebniak A, BelAiba RS, et al. The expression of the NADPH oxidase subunit p22phox is regulated by a redoxsensitive pathway in endothelial cells. Free Radic Biol Med 2005; 38(5): 616-30.
142. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111(8): 1201-9.
143. McNally JS, Saxena A, Cai H, Dikalov S, Harrison DG. Regulation of xanthine oxidoreductase protein expression by hydrogen peroxide and calcium. Arterioscler Thromb Vasc Biol 2005; 25(8): 1623-8.
144. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 2006; 1757(5-6): 509-17.
145. Zafari AM, Ushio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32(3): 488-95.
146. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74(6): 1141-8.
147. Hingtgen SD, Tian X, Yang J, et al. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin IIinduced cardiomyocyte hypertrophy. Physiol Genomics 2006; 26(3): 180-91.
148. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003; 35(7): 851-9.
149. Reeves EP, Dekker LV, Forbes LV, et al. Direct interaction between p47phox and protein kinase C: evidence for targeting of protein kinase C by p47phox in neutrophils. Biochem J 1999; 344 Pt 3: 859-66.
150. Fontayne A, Dang PM, Gougerot-Pocidalo MA, El-Benna J. Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry 2002; 41(24): 7743-50.
151. Hoyal CR, Gutierrez A, Young BM, et al. Modulation of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc Natl Acad Sci USA 2003; 100(9): 5130-5.
152. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: more than a binary GTP switch. Am J Physiol Cell Physiol 2003; 285(4): C723-34.
153. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91(5): 406-13.
154. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci USA 2006; 103(19): 7432-7.
155. Welch HC, Coadwell WJ, Stephens LR, Hawkins PT. Phosphoinositide 3-kinase-dependent activation of Rac. FEBS Lett 2003; 546(1): 93-7.
156. Price MO, Atkinson SJ, Knaus UG, Dinauer MC. Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent. J Biol Chem 2002; 277(21): 19220-8.
157. Vecchione C, Patrucco E, Marino G, et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J Exp Med 2005; 201(8): 1217-28.
158. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H(2)O(2) regulates cardiac myocyte phenotype via concentrationdependent activation of distinct kinase pathways. J Mol Cell Cardiol 2003; 35(6): 615-21.
159. Blanc A, Pandey NR, Srivastava AK. Synchronous activation of ERK 1/2, p38mapk and PKB/Akt signaling by H2O2 in vascular smooth muscle cells: potential involvement in vascular disease (review). Int J Mol Med 2003; 11(2): 229-34.
160. Pimentel DR, Adachi T, Ido Y, et al. Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen speciesdependent Ras S-glutathiolation. J Mol Cell Cardiol 2006; 41(4): 613-22.
161. Ushio-Fukai M, Alexander RW, Akers M, et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999; 274(32): 22699-704.
162. Kawakami M, Okabe E. Superoxide anion radical-triggered Ca2+ release from cardiac sarcoplasmic reticulum through ryanodine receptor Ca2+ channel. Mol Pharmacol 1998; 53(3): 497-503.
163. Zeng Q, Zhou Q, Yao F, O'Rourke ST, Sun C. Endothelin-1 regulates cardiac L-type calcium channels via NAD(P)H oxidasederived superoxide. J Pharmacol Exp Ther 2008; 326(3): 732-8.
164. Amberg GC, Earley S, Glapa SA. Local Regulation of Arterial LType Calcium Channels by Reactive Oxygen Species. Circ Res.
165. Li PF, Dietz R, von Harsdorf R. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac fibroblasts. FEBS Lett 1999; 448(2-3): 206-10.
166. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 2002; 8(3): 132-40.
167. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002; 8(1): 35-40.
168. Ohtsu H, Dempsey PJ, Frank GD, et al. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 2006; 26(9): e133-7.
169. Daub H, Weiss FU, Wallasch C, Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379(6565): 557-60.
170. Lautrette A, Li S, Alili R, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11(8): 867-74.
171. Shah BH, Shah FB, Catt KJ. Role of metalloproteinase-dependent EGF receptor activation in alpha-adrenoceptor-stimulated MAP kinase phosphorylation in GT1-7 neurons. J Neurochem 2006; 96(2): 520-32.
172. Castro MM, Rizzi E, Figueiredo-Lopes L, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198(2): 320-31.
173. Herget J, Novotna J, Bibova J, Povysilova V, Vankova M, Hampl V. Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2003; 285(1): L199-208.
174. Guimaraes DA, Rizzi E, Ceron CS, et al. Doxycycline dosedependently Inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol 2011; 108(5): 318-25.
175. Miura S, Ohno I, Suzuki J, et al. Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by betaadrenergic stimulation in rats. J Cardiovasc Pharmacol 2003; 42(2): 174-81.
176. Hao L, Nishimura T, Wo H, Fernandez-Patron C. Vascular responses to alpha1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler Thromb Vasc Biol 2006; 26(4): 819-25.
177. Wang X, Chow FL, Oka T, et al. Matrix Metalloproteinase-7 and ADAM-12 (a Disintegrin and Metalloproteinase-12) Define a Signaling Axis in Agonist-Induced Hypertension and Cardiac Hypertrophy. Circulation 2009.
178. Wang X, Oka T, Chow FL, et al. Tumor necrosis factor-alphaconverting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009; 54(3): 575-82.
179. Odenbach J, Wang X, Cooper S, et al. MMP-2 Mediates Angiotensin II-Induced Hypertension Under the Transcriptional Control of MMP-7 and TACE. Hypertension.
180. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A 1990; 87(14): 5578-82.
181. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87(4): 1285-342.
182. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999; 9(24): 1441-7.
183. Hayami T, Funaki H, Yaoeda K, et al. Expression of the cartilage derived anti-angiogenic factor chondromodulin-I decreases in the early stage of experimental osteoarthritis. J Rheumatol 2003; 30(10): 2207-17.
184. DeLano FA, Schmid-Schonbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension 2008; 52(2): 415-23.
185. Tran ED, DeLano FA, Schmid-Schonbein GW. Enhanced matrix metalloproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res; 47(5): 423-31.
186. Nagareddy PR, Chow FL, Hao L, et al. Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis. Cardiovasc Res 2009; 84(3): 368-77.
187. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol 1997; 15(8-9): 519-26.
188. Lin CW, Georgescu HI, Evans CH. The role of AP-1 in matrix metalloproteinase gene expression. Agents Actions 1993; 39 Spec No: C215-8.
189. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164(5): 769-79.
190. Kurohara K, Komatsu K, Kurisaki T, et al. Essential roles of Meltrin beta (ADAM19) in heart development. Dev Biol 2004; 267(1): 14-28.
191. Ancha HR, Kurella RR, Stewart CA, Damera G, Ceresa BP, Harty RF. Histamine stimulation of MMP-1(collagenase-1) secretion and gene expression in gastric epithelial cells: role of EGFR transactivation and the MAP kinase pathway. Int J Biochem Cell Biol 2007; 39(11): 2143-52.
192. Coker ML, Jolly JR, Joffs C, et al. Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol 2001; 281(2): H543-51.
193. Tsukioka K, Suzuki J, Fujimori M, et al. Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc Res 2002; 56(3): 472-8.
194. Moshal KS, Sen U, Tyagi N, et al. Regulation of homocysteineinduced MMP-9 by ERK1/2 pathway. Am J Physiol Cell Physiol 2006; 290(3): C883-91.
195. Taniguchi Y, Doronbekov K, Yamada T, Sasaki Y, Takano A, Sugimoto Y. Genomic organization and promoter analysis of the bovine ADAM12 gene. Anim Biotechnol 2008; 19(3): 178-89.
196. Saygili E, Rana OR, Meyer C, et al. The angiotensin-calcineurin-NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytes. Basic Res Cardiol 2009; 104(4): 435-48.
197. Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. Embo J 1998; 17(24): 7260-72.
198. Diaz-Rodriguez E, Montero JC, Esparis-Ogando A, Yuste L, Pandiella A. Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell 2002; 13(6): 2031-44.
199. Zheng Y, Schlondorff J, Blobel CP. Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1. J Biol Chem 2002; 277(45): 42463-70.
200. Zhang Z, Oliver P, Lancaster JJ, et al. Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate. FASEB J 2001; 15(2): 303-5.
201. Mifune M, Ohtsu H, Suzuki H, et al. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 2005; 280(28): 26592-9.
202. Mori S, Tanaka M, Nanba D, et al. PACSIN3 binds ADAM12/meltrin alpha and up-regulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 2003; 278(46): 46029-34.
203. Tanaka M, Nanba D, Mori S, et al. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem 2004; 279(40): 41950-9.
204. Beklen A, Tuter G, Sorsa T, et al. Gingival tissue and crevicular fluid co-operation in adult periodontitis. J Dent Res 2006; 85(1): 59-63.
205. Salo J, Mackiewicz Z, Indahl A, et al. Plasmin-matrix metalloproteinase cascades in spinal response to an experimental disc lesion in pig. Spine (Phila Pa 1976) 2008; 33(8): 839-44.
206. Dozier S, Escobar GP, Lindsey ML. Matrix metalloproteinase (MMP)-7 activates MMP-8 but not MMP-13. Med Chem 2006; 2(5): 523-6.
207. Zhan M, Jin B, Chen SE, Reecy JM, Li YP. TACE release of TNFalpha mediates mechanotransduction-induced activation of p38 MAPK and myogenesis. J Cell Sci 2007; 120(Pt 4): 692-701.
208. Mohan S, Thompson GR, Amaar YG, Hathaway G, Tschesche H, Baylink DJ. ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry 2002; 41(51): 15394-403.
209. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275(24): 18574-80.
210. Coppock HA, White A, Aplin JD, Westwood M. Matrix metalloprotease-3 and-9 proteolyze insulin-like growth factorbinding protein-1. Biol Reprod 2004; 71(2): 438-43.
211. Edwin F, Wiepz GJ, Singh R, et al. A historical perspective of the EGF receptor and related systems. Methods Mol Biol 2006; 327: 1-24.
212. Karunagaran D, Tzahar E, Beerli RR, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Embo J 1996; 15(2): 254-64.
213. Clerk A, Aggeli IK, Stathopoulou K, Sugden PH. Peptide growth factors signal differentially through protein kinase C to extracellular signal-regulated kinases in neonatal cardiomyocytes. Cell Signal 2006; 18(2): 225-35.
214. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273(17): 10261-9.
215. Merkel LA, Rivera LM, Colussi DJ, Perrone MH. Inhibition of EGF-induced vasoconstriction in isolated rabbit aortic rings with the tyrosine kinase inhibitor RG50864. Biochem Biophys Res Commun 1993; 192(3): 1319-26.
216. Florian JA, Watts SW. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol 1999; 276(3 Pt 2): H976-83.
217. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002; 106(8): 909-12.
218. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 2003; 22(5): 1114-24.
219. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284(1): 31-53.
220. Zuo L, Ushio-Fukai M, Ikeda S, Hilenski L, Patrushev N, Alexander RW. Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy. Arterioscler Thromb Vasc Biol 2005; 25(9): 1824-30.
221. Zuo L, Ushio-Fukai M, Hilenski LL, Alexander RW. Microtubules regulate angiotensin II type 1 receptor and Rac1 localization in caveolae/lipid rafts: role in redox signaling. Arterioscler Thromb Vasc Biol 2004; 24(7): 1223-8.
222. Schlessinger J, Lemmon MA. SH2 and PTB domains in tyrosine kinase signaling. Sci STKE 2003; 2003(191): RE12.
223. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000; 19(13): 3159-67.
224. Touyz RM, Cruzado M, Tabet F, Yao G, Salomon S, Schiffrin EL. Redox-dependent MAP kinase signaling by Ang II in vascular smooth muscle cells: role of receptor tyrosine kinase transactivation. Can J Physiol Pharmacol 2003; 81(2): 159-67.
225. Bae YS, Kang SW, Seo MS, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptormediated tyrosine phosphorylation. J Biol Chem 1997; 272(1): 217-21.
226. Rao GN, Delafontaine P, Runge MS. Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. J Biol Chem 1995; 270(46): 27871-5.
227. Linseman DA, Benjamin CW, Jones DA. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 1995; 270(21): 12563-8.
228. Kelly DJ, Cox AJ, Gow RM, Zhang Y, Kemp BE, Gilbert RE. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 2004; 44(2): 195-202.
229. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000; 275(29): 22583-9.
230. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001; 21(19): 6387-94.
231. Munoz JP, Collao A, Chiong M, et al. The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling. Biochem Biophys Res Commun 2009; 388(1): 155-60.
232. Huang CY, Hao LY, Buetow DE. Insulin-like growth factor-II induces hypertrophy of adult cardiomyocytes via two alternative pathways. Cell Biol Int 2002; 26(8): 737-9.
233. Huang CY, Hao LY, Buetow DE. Insulin-like growth factorinduced hypertrophy of cultured adult rat cardiomyocytes is L-type calcium-channel-dependent. Mol Cell Biochem 2002; 231(1-2): 51-9.
234. Ponten A, Li X, Thoren P, et al. Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol 2003; 163(2): 673-82.
235. Heeneman S, Haendeler J, Saito Y, Ishida M, Berk BC. Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J Biol Chem 2000; 275(21): 15926-32.
236. LaRochelle WJ, Jeffers M, McDonald WF, et al. PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001; 3(5): 517-21.
237. Li X, Ponten A, Aase K, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000; 2(5): 302-9.
238. Lim JY, Park SJ, Hwang HY, et al. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol 2005; 39(4): 627-36.
239. Rosenkranz S, Flesch M, Amann K, et al. Alterations of betaadrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002; 283(3): H1253-62.
240. Ge G, Greenspan DS. BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 2006; 175(1): 111-20.
241. Watkins SJ, Jonker L, Arthur HM. A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy. Cardiovasc Res 2006; 69(2): 432-9.
242. Moriguchi T, Kuroyanagi N, Yamaguchi K, et al. A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem 1996; 271(23): 13675-9.
243. Zhang D, Gaussin V, Taffet GE, et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000; 6(5): 556-63.
244. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 1999; 274(13): 8949-57.
245. Monzen K, Hiroi Y, Kudoh S, et al. Smads, TAK1, and their common target ATF-2 play a critical role in cardiomyocyte differentiation. J Cell Biol 2001; 153(4): 687-98.
246. Herron TJ, Vandenboom R, Fomicheva E, Mundada L, Edwards T, Metzger JM. Calcium-independent negative inotropy by betamyosin heavy chain gene transfer in cardiac myocytes. Circ Res 2007; 100(8): 1182-90.
247. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95(5): 1247-52.
248. Dibbs ZI, Diwan A, Nemoto S, et al. Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation 2003; 108(8): 1002-8.
249. Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension 2008; 51(5): 1345-51.
250. Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 2004; 279(41): 42898-906.
251. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 2000; 105(2): 143-50.
252. Gearing AJ, Beckett P, Christodoulou M, et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 1995; 57(5): 774-7.
253. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370(6490): 555-7.
254. Condorelli G, Morisco C, Latronico MV, et al. TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor. FASEB J 2002; 16(13): 1732-7.
255. Hiraoka E, Kawashima S, Takahashi T, et al. TNF-alpha induces protein synthesis through PI3-kinase-Akt/PKB pathway in cardiac myocytes. Am J Physiol Heart Circ Physiol 2001; 280(4): H1861-8.
256. Liu PC, Liu X, Li Y, et al. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 2006; 5(6): 657-64.
257. Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schonbein GW. Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol; 299(1): H25-35.
258. Chen AY, DeLano FA, Valdez SR, Ha JN, Shin HY, Schmid-Schonbein GW. Receptor cleavage reduces the fluid shear response in neutrophils of the spontaneously hypertensive rat. Am J Physiol Cell Physiol 2010; 299(6): C1441-9.
259. Yamazato Y, Ferreira AJ, Hong KH, et al. Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 2009; 54(2): 365-71.
260. Boadle MC, Hughes J, Roth RH. Angiotensin accelerates catecholamine biosynthesis in sympathetically innervated tissues. Nature 1969; 222(5197): 987-8.
261. Cox SL, Ben A, Story DF, Ziogas J. Evidence for the involvement of different receptor subtypes in the pre-and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol 1995; 114(5): 1057-63.
262. Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983; 18(5): 516-26.
263. Maitra SR, Bhaduri S, Valane PD, Tervahartiala T, Sorsa T, Ramamurthy N. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock 2003; 20(3): 280-5.
264. Steinberg J, Halter J, Schiller HJ, et al. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res 2003; 111(2): 185-95.
265. Salo T, Soini Y, Oiva J, et al. Chemically modified tetracyclines (CMT-3 and CMT-8) enable control of the pathologic remodellation of human aortic valve stenosis via MMP-9 and VEGF inhibition. Int J Cardiol 2006; 111(3): 358-64.
266. Lokeshwar BL. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol Res 2011; 63(2): 146-50.
267. Richards C, Pantanowitz L, Dezube BJ. Antimicrobial and nonantimicrobial tetracyclines in human cancer trials. Pharmacol Res 2011; 63(2): 151-6.
268. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9(1): 63-79.
269. Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004; 22(23): 4683-90.
270. Guimaraes DA, Rizzi E, Ceron CS, et al. Doxycycline dosedependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol; 108(5): 318-25.
271. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, Garner HR. Doxycycline attenuates isoproterenol-and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther 2008; 324(3): 1196-203.
272. Camp TM, Tyagi SC, Aru GM, Hayden MR, Mehta JL. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 2004; 23(6): 729-36.
273. Hudson MP, Armstrong PW, Ruzyllo W, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006; 48(1): 15-20.
274. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24(4): 733-8.
275. Sang QX, Jin Y, Newcomer RG, et al. Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 2006; 6(4): 289-316.
276. Dorman G, Kocsis-Szommer K, Spadoni C, Ferdinandy P. MMP inhibitors in cardiac diseases: an update. Recent Pat Cardiovasc Drug Discov 2007; 2(3): 186-94.